

Curriculum Vitae

Personal information Thijs Ambagts

Work experience

september 2023 - present Assessor Pharmacovigilance

april 2021- july 2023 pharmacist at Dutch Institute for Rationl Use of medicines

july 2016 - september 2022 Responsible pharmacist at pubic pharmacies in Katwijk, Rijnsburg, Sassenheim, Voorhout and Valkenburg, at Sloothaak BV pharmacies

june 2012- april 2016 Responsible pharmacist at Boots pharmacies in Leiden and Hazerswoude dorp

may 2011- may 2012 Productmanager Pharmaotherapy at the the Dutch drug Database at the Royal association for the advancement of pharmacy

june 2009- april 2011 Responsible Pharmacist at cooperating pharmacies "Berg & Vos" and "Dr. J.C. de Keuning".

sept 2008 - may 2009 Project pharmacst in the Hospital pharmacy at Alrijne group Leiden

april 2001 - August 2005 $\,$ PhD Candidate at the department Human and Clinical Genetics division 5 of the Leiden University Medical Centre

Education and training

sept 2005 - november 2008 Pre-master plus Master in Pharmaceutical Sciences (MSc, University of Utrecht)

april 2001- august 2005 PhD candidate Role of Fcgamma receptors in the development and progression of atherosclerosis using (inducicble) Knock out/ knock in mouse models and (MSc, University of Leiden)

september 1996- april 2001 Bio Pharmaceutical Sciences (MSC, University of Leiden)

Additional information

Publications

2023 (contributed to) A 12 gene panel to prevent adverse drug reaction.... Lancet Feb 4;401(10374):347-356. 2022 Annual Theme report Medication Safety for the Institute of Rational Use of Medicines (in Dutch: Medicatieveiligheid, IVM)

2019 Metformine slow release "net zo effectief, soms meer gebruiksgemak", Pharmaceutical Weekly journal issue

2014 Verhoogd risico Pneumonie door gebruik inhalatiecorticosteroïden, Pharma Selecta no. 9 2014 2008 P55 tumour necrosis factor receptor in bone marrow-derived cellsLDLreceptor KO mice. Cardiovasc Res. 2008 Jul 15.

2002 Peroral delivery systems based on SPH polymers: release characteristics for the peptide drugs buserelin, octreotide and insulin. Eur J Pharm Sci. 2002 Jun; 15(5):433-9.

Projects

2021 – 2023 Member Special Interest Group Oxytocin, IMSN (International Medication Safety Network)
2017- 2019 Member Special Interest Group Diabetes, KNMP
2016- 2019 Member Committee for Veterinary Medicinal Products, Medicines Evaluation Board

Memberships

Other Relevant Information